Article
Oncology
Di Maria Jiang, Hao-Wen Sim, Osvaldo Espin-Garcia, Bryan A. Chan, Akina Natori, Charles H. Lim, Stephanie Moignard, Eric X. Chen, Geoffrey Liu, Gail Darling, Carol J. Swallow, Savtaj Brar, James Brierley, Jolie Ringash, Rebecca Wong, John Kim, Patrik Rogalla, Sara Hafezi-Bakhtiari, Jennifer J. Knox, Raymond W. Jang, Elena Elimova
Summary: A retrospective study found similar outcomes between using CP and CF in TMT for esophageal or GEJ cancer patients, but CF may be a superior regimen in the setting of dCRT.
Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Wenwu He, Xuefeng Leng, Tianqin Mao, Xi Luo, Lingxiao Zhou, Jiaxin Yan, Lin Peng, Qiang Fang, Guangyuan Liu, Xing Wei, Kangning Wang, Chenghao Wang, Sha Zhang, Xudong Zhang, Xudong Shen, Depei Huang, Huan Yi, Ting Bei, Xueke She, Wenguang Xiao, Yongtao Han
Summary: This study focuses on locally advanced resectable esophageal squamous cell carcinoma (ESCC), investigating the safety, feasibility, and efficacy of neoadjuvant toripalimab plus paclitaxel and carboplatin treatment. The results indicate that this combination therapy shows potential as a neoadjuvant treatment for ESCC, with increased CD8(+) T cells and decreased M2-type tumor-associated macrophages in responders. Furthermore, certain molecular signatures were associated with treatment response.
Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
G. E. Konecny, A. E. Wahner Hendrickson, T. M. Davidson, B. J. Winterhoff, S. Ma, S. Mahner, J. Sehouli, P. A. Fasching, G. Feisel-Schwickardi, M. Poelcher, L. D. Roman, A. Rody, B. Y. Karlan, S. A. Mullany, H. Chen, I. L. Ray-Coquard, D. M. Provencher, A. Yachnin, P. H. Cottu, J. A. Glaspy, P. Haluska, D. J. Slamon
Summary: This study investigated the efficacy and safety of adding ganitumab to CP chemotherapy in primary EOC patients, but did not show improvement in PFS. The results do not support further study of ganitumab in unselected EOC patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone
Summary: This study compared carboplatin and paclitaxel with avelumab plus carboplatin and paclitaxel as first-line treatment in patients with advanced or recurrent endometrial cancer. The addition of avelumab showed potential for improving progression-free survival, but further investigation is needed.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Biochemistry & Molecular Biology
Helena Branco, Julio Oliveira, Catarina Antunes, Lucio L. Santos, Maria Helena Vasconcelos, Cristina P. R. Xavier
Summary: This study investigated the potential of using Pirfenidone to enhance the sensitivity of non-small cell lung cancer (NSCLC) cells to chemotherapy. The results showed that Pirfenidone increased the effectiveness of paclitaxel treatment on NSCLC cells without increasing toxicity in non-tumorigenic cells. This research suggests the possibility of repurposing Pirfenidone in combination with chemotherapy for treating NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Maria Rubinstein, Sherry Shen, Bradley J. Monk, David S. P. Tan, Angelica Nogueira-Rodrigues, Daisuke Aoki, Jalid Sehouli, Vicky Makker
Summary: Incidence and mortality of endometrial cancer are increasing among all ethnic groups. Carboplatin plus paclitaxel is the frontline treatment, but subsequent traditional cytotoxic chemotherapy is challenging. Molecular characterization has led to the development of precision immunotherapies and targeted therapies. The applicability of platinum rechallenge is subjective and limited by small retrospective studies.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Mohammed Al-Jumayli, Khalil Choucair, Ammar Al-Obaidi, Robin Park, Ajay Bansal, Joaquina Baranda, Weijing Sun, Anwaar Saeed
Summary: This study compared the efficacy and tolerability of two chemotherapy regimens in older patients with advanced esophageal cancer. The results showed that the less toxic CP regimen can achieve similar tumor response and survival rates as the P5F chemotherapy in older patients.
ANTICANCER RESEARCH
(2022)
Article
Immunology
Maojin You, Xiaoling Zeng, Jinrong Zhang, Yufan Huang, Yalan Zhang, Zhongjie Cai, Yingying Hu
Summary: This study evaluated the cost-effectiveness of DOS-CP compared to PLB-CP as a first-line treatment for advanced EC. The findings suggest that DOS-CP is unlikely to be a cost-effective treatment option from the perspective of the Chinese healthcare system.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Xiangbin Tan, Shuangyou Zou, Hui Chen, Dachao Chen
Summary: This study compared the efficacy of paclitaxel liposomes combined with carboplatin and paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer. The results showed that paclitaxel liposomes combined with carboplatin had a higher overall response rate and could reduce serum marker levels and the occurrence of adverse reactions.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2023)
Article
Medicine, Research & Experimental
Po-Hsu Su, Shun-Wen Hsueh, Chen-Kan Tseng, Ming-Mo Ho, Po-Jung Su, Chia-Yen Hung, Kun-Yun Yeh, Pei-Hung Chang, Yu-Shin Hung, Ya -Wen Ho, Yu-Ching Lin, Wen-Chi Chou
Summary: In patients with locally advanced esophageal cancer, neoadjuvant chemoradiotherapy with Pac/Car showed superior survival outcomes, higher surgical resection rate, and better safety profiles compared to Cis/5Fu.
Article
Oncology
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Summary: Despite the underrepresentation of certain patient populations in clinical trials for advanced NSCLC, a pooled analysis of elderly patients and those with renal impairment, diabetes, or poor performance status showed varying but promising outcomes, supporting the use of nab-paclitaxel-based regimens in these historically understudied and vulnerable populations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yingxia Wen, Hung V. Trinh, Christine E. Linton, Chiara Tani, Nathalie Norais, DeeAnn Martinez-Guzman, Priyanka Ramesh, Yide Sun, Frank Situ, Selen Karaca-Griffin, Christopher Hamlin, Sayali Onkar, Sai Tian, Susan Hilt, Padma Malyala, Rushit Lodaya, Ning Li, Gillis Otten, Giuseppe Palladino, Kristian Friedrich, Yukti Aggarwal, Celia LaBranche, Ryan Duffy, Xiaoying Shen, Georgia D. Tomaras, David C. Montefiori, William Fulp, Raphael Gottardo, Brian Burke, Jeffrey B. Ulmer, Susan Zolla-Pazner, Hua-Xin Liao, Barton F. Haynes, Nelson L. Michael, Jerome H. Kim, Mangala Rao, Robert J. O'Connell, Andrea Carfi, Susan W. Barnett
Article
Otorhinolaryngology
Laura Martin-Gomez, Anna R. Giuliano, William J. Fulp, Jimmy Caudell, Michelle Echevarria, Bradley Sirak, Martha Abrahamsen, Kimberly A. Isaacs-Soriano, Juan C. Hernandez-Prera, Bruce M. Wenig, Kathryn Vorwald, Caitlin P. McMullen, J. Trad Wadsworth, Robbert J. Slebos, Christine H. Chung
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2019)
Article
Oncology
Laura Martin-Gomez, William J. Fulp, Michael J. Schell, Bradley Sirak, Martha Abrahamsen, Kimberly A. Isaacs-Soriano, Attila Lorincz, Bruce Wenig, Christine H. Chung, Jimmy J. Caudell, Anna R. Giuliano
Article
Oncology
Dung-Tsa Chen, Michael J. Schell, William J. Fulp, Fredrik Pettersson, Sungjune Kim, Jhanelle E. Gray, Eric B. Haura
TRANSLATIONAL CANCER RESEARCH
(2019)
Article
Surgery
Benjamin D. Powers, William Fulp, Amina Dhahri, Danielle K. DePeralta, Takuya Ogami, Luke Rothermel, Jennifer B. Permuth, Susan T. Vadaparampil, Joon-Kyung Kim, Jose Pimiento, Pamela J. Hodul, Mokenge P. Malafa, Daniel A. Anaya, Jason B. Fleming
Summary: This study found that socioeconomic status did not significantly impact the treatment quality and survival of pancreatic cancer patients at a high-volume cancer center with a standardized clinical pathway.
Article
Immunology
Kristen A. Stafford, Bryan T. Mayer, William Fulp, Joel Chua, Charles Davis, Bruce Gilliam, Dan Dong, Robert C. Gallo, Mohammad M. Sajadi
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2020)
Article
Oncology
James Sun, Brittany J. Mathias, Weihong Sun, William J. Fulp, Jun-Min Zhou, Christine Laronga, Loretta S. Loftus, M. Catherine Lee
Summary: This study examined the impact of SLNB on treatment and outcomes in breast cancer patients aged >= 70 years who were clinically node-negative and hormone receptor-positive. The results indicated that SLN-negative patients had better overall survival and less distant recurrence, while adjuvant hormone therapy significantly improved overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Brittany J. Mathias, James Sun, Weihong Sun, Jun-Min Zhou, William J. Fulp, Christine Laronga, M. Catherine Lee, John Kiluk
Summary: The study evaluates the factors that led surgeons to forego CALND in cN0 mastectomy patients with positive SLNB. Younger age, larger tumors, increased number of positive sentinel nodes, invasive lobular carcinoma, extranodal extension, and lymphovascular invasion were significantly associated with delayed CALND.
CLINICAL BREAST CANCER
(2021)
Article
Immunology
Sudhir Pai Kasturi, Mohammed Ata Ur Rasheed, Colin Havenar-Daughton, Mathew Pham, Traci Legere, Zarpheen Jinnah Sher, Yevgeny Kovalenkov, Sanjeev Gumber, Jessica Y. Huang, Raphael Gottardo, William Fulp, Alicia Sato, Sheetal Sawant, Sherry Stanfield-Oakley, Nicole Yates, Celia LaBranche, S. Munir Alam, Georgia Tomaras, Guido Ferrari, David Montefiori, Jens Wrammert, Francois Villinger, Mark Tomai, John Vasilakos, Christopher B. Fox, Steven G. Reed, Barton F. Haynes, Shane Crotty, Rafi Ahmed, Bali Pulendran
SCIENCE IMMUNOLOGY
(2020)
Article
Biology
Virginie Rozot, Elisa Nemes, Hennie Geldenhuys, Munyaradzi Musvosvi, Asma Toefy, Frances Rantangee, Lebohang Makhethe, Mzwandile Erasmus, Nicole Bilek, Simbarashe Mabwe, Greg Finak, William Fulp, Ann M. Ginsberg, David A. Hokey, Muki Shey, Sanjay Gurunathan, Carlos DiazGranados, Linda-Gail Bekker, Mark Hatherill, Thomas J. Scriba
COMMUNICATIONS BIOLOGY
(2020)
Article
Oncology
James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John Kiluk, M. Catherine Lee
Summary: The study found that completion axillary lymph node dissection (CLND) after mastectomy did not significantly reduce recurrence or improve overall survival (OS) in clinically node-negative, sentinel lymph node (SLN)-positive breast cancer patients. However, completion of postmastectomy radiotherapy was associated with improved OS.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Immunology
Joel V. Chua, Charles Davis, Jennifer S. Husson, Amy Nelson, Ilia Prado, Robin Flinko, Ka Wing J. Lam, Lydiah Mutumbi, Bryan T. Mayer, Dan Dong, William Fulp, Celia Mahoney, Monica Gerber, Raphael Gottardo, Bruce L. Gilliam, Kelli Greene, Hongmei Gao, Nicole Yates, Guido Ferrari, Georgia Tomaras, David Montefiori, Jennifer A. Schwartz, Timothy Fouts, Anthony L. DeVico, George K. Lewis, Robert C. Gallo, Mohammad M. Sajadi
Summary: The IHV01 vaccine is a safe, well tolerated, and immunogenic FLSC vaccine construct capable of eliciting broadly reactive antibody responses against conserved CD4i epitopes, mediating antiviral functions.
Article
Oncology
George Yang, Zhigang Yuan, Kamran Ahmed, Eric A. Welsh, William J. Fulp, Ricardo J. Gonzalez, John E. Mullinax, Douglas Letson, Marilyn Bui, Louis B. Harrison, Jacob G. Scott, Javier F. Torres-Roca, Arash O. Naghavi
Summary: By analyzing the genomic sensitivity of soft-tissue sarcomas, we identified a subset of highly radioresistant tumors with lower tumor response to radiation and locoregional control rates. Using GARD, we calculated the radiation dose required to optimize outcome in this subset.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Virology
Deepti Bettampadi, Bradley A. Sirak, William J. Fulp, Martha Abrahamsen, Luisa L. Villa, Eduardo Lazcano-Ponce, Jorge Salmeron, Kimberly A. Isaacs-Soriano, Maria L. Baggio, Manuel Quiterio Trenado, Anna R. Giuliano
PAPILLOMAVIRUS RESEARCH
(2020)
Article
Oncology
Zhigang Yuan, G. Daniel Grass, Mounsif Azizi, Kamran A. Ahmed, G. Sean J. Yoder, Eric A. Welsh, William J. Fulp, Jasreman Dhillon, Javier F. Torres-Roca, Anna R. Giuliano, Philippe E. Spiess, Peter A. Johnstone
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY
(2019)